DELRAY BEACH, Fla., May 2, 2017 /PRNewswire-USNewswire/ -- The Sperling Prostate Center is pleased to announce its participation as a new study site for a clinical study of MR-guided focused ultrasound (MRgFUS) for the focal treatment of localized low and intermediate risk prostate lesions. They are now recruiting patients.
The Sperling Prostate Center is a diagnosis and treatment center with locations in Florida and New York City. The Center is headed by Dan Sperling, M.D., D.A.B.R., a renowned expert in the use of Magnetic Resonance Imaging (MRI) technology for the diagnosis and treatment of prostate lesions.
"We are excited to join this study to evaluate MR-guided focused ultrasound as a non-invasive and non-radiation treatment option for prostate cancer patients who may currently be on watchful waiting or active surveillance," states Dr. Sperling.
The Exablate Prostate system is based on INSIGHTEC's proven MRI-guided focused ultrasound technology which received its CE mark in December 2016. It uses focused ultrasound waves to precisely ablate (destroy) the identified prostate lesion. The treatment is done under MRI for visualization of the patient's anatomy as well as real-time temperature monitoring. The treatment does not require incisions and is performed in a single session, allowing patients to quickly return to normal activity.
Men who are interested in participating in the clinical trial should call Malissa Owen at the Sperling Prostate Center, (561) 300-1363, for evaluation of suitability.
About Sperling Prostate Center
Sperling Prostate Center is a global leader in advanced 3T MRI-based detection, diagnosis and treatment of prostate cancer tumors. The Center is located at 4205 W. Atlantic Ave, Bldg. D, Delray Beach, FL 33445. Learn more at www.sperlingprostatecenter.com.